Trial Profile
Phase IIIb open label study of afatinib in a broad population of EGFR TKI-naïve patients with EGFRm+ NSCLC.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 10 Sep 2019 Results of final analysis of this trial presented at the 20th World Conference on Lung Cancer